



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

**Illinois Drug Utilization Review
Board Meeting Minutes
April 27, 2023**

I. Call to Order, Roll Call

- a. Call to order
 - i. Dr. Schriever called the meeting to order at 8:31am.
 - ii. Meeting conducted via a Webex webinar format.
 - iii. Jen Dewitt made the announcement that the meeting was being recorded in accordance with the Open Meetings Act and that public comments will be made later in the meeting and any guests wishing to speak please type name, affiliation, and that you would like to speak in the Webex chat. Five minutes will be allotted to each guest to speak.
- b. Roll call
 - i. Roll call was taken, and a quorum was established. All DUR Board members were present.

II. Agenda, conflict of interest review, and approval of January 26, 2023 meeting minutes

- a. January 26, 2023 meeting minutes- No changes or additions. Motion to approve made by Dr. Sreedhar, seconded by Dr. An.
- b. Vote: In favor- 4 / Against- 0 / Abstentions- 0. January 26, 2023 meeting minutes approved.
- c. No changes to the April 27, 2023 agenda were requested.
- d. No DUR Board members had conflicts of interest pertinent to the agenda. Dr. Schriever reminded DUR Board members to recuse themselves from discussion if conflicts of interest are present and to provide an updated *Conflict of Interest* form if new conflicts arise.

III. Quarterly Reports – presented by Maurice Shaw, PharmD

- a. Top 10 spend Fee-For-Service (FFS) drugs (2023Q1)
- b. Top 10 script count FFS- Prescription only (2023Q1)
- c. Top 10 script count FFS- OTC only (2023Q1)
- d. Top 5 script count by disease state: Diabetes (FFS and Managed Care Organization (MCO), 2022Q4)
 - i. Dr. Nikocecic would like to see the number of scripts and a percentage of all scripts that were filled in FFS vs MCO.
- e. Top 5 script count by disease state: Hypertension (FFS and MCO, 2022Q4)
 - i. The board would like to see what the diagnoses for clonidine and prazosin are since neither drug is indicated as first-line treatment for hypertension.
- f. Top 5 script count by disease state: Depression (FFS and MCO, 2022Q4)
- g. Top 5 script count by disease state: Asthma (FFS and MCO, 2022Q4)
- h. Prior authorization approvals and denials (2023Q1)
 - i. Percentages are similar to those presented at the January meeting.
- i. Clinical denial reasons (2023Q1)
 - i. Dr. Sreedhar would like to see a list of the top drugs that are denied.
 - ii. Dr. Goyal asked if at the next meeting a number or percentage of prior authorizations that were initially rejected due to insufficient medical justification, then later approved can be provided.



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

IV. RetroDUR 300 – presented by Christina Petrykiw, PharmD, CDCES

a. RetroDUR 300

- i. RDUR is an automated provided by Change Healthcare.
- ii. Study 24: 300 patients with more than one issue identified.
- iii. As of April 2023, 38 patients- FFS, rest are MCO, Medicare, or third-party insurance; no HFS coverage; deceased
 1. Daily dose less than recommended daily dose range or dose for dosage form- 134
 2. Duplicate therapy- 53
 3. Pharmacist identified issue- 13
- iv. Issues identified by pharmacist reviewer
 1. Potassium level with furosemide and Entresto; extended courses of antibiotics/antifungals; montelukast use with no asthma/allergy diagnosis; smoking cessation with COPD; SMART therapy candidate for asthma; naloxone indicated; diabetes- diagnosis with no T2DM medications, concomitant Januvia and Humalog, concomitant canagliflozin and empagliflozin for 3 months, adjust diabetes medication regimens to include SGLT2i or GLP-1 RA due to concomitant ASCVD, CKD, or HF presence.
- v. Discussion
 1. Prescriber outreach ongoing.
 2. Possible duplicate therapy edits needed:
 - a. SGLT2i
 - b. GLP-1 RA
 - c. Januvia and rapid/short-acting insulins
 - d. Metoprolol tartrate and metoprolol succinate
 - e. Famotidine and proton pump inhibitor
 3. Board discussion
 - a. There was discussion about turning on all edits for duplicate therapy that MediSpan provides, but Jen Dewitt said that if all duplicate therapy edits were turned on, so many alerts would fire that it would likely interfere with patients getting their medications.
 - b. Jen DeWitt will bring the duplicate therapy edits currently programmed in PBMS to the next meeting.
 - c. Dr. Schriever made a motion that the duplicate therapy edits for the above drugs be implemented in PBMS, seconded by Dr. Sreedhar.
 - d. Vote: In favor- 4 / Against- 0 / Abstentions- 0
 - e. Motion passes.

V. Prospective DUR: Trulicity® (dulaglutide) Usage – Presented by Maurice Shaw, PharmD

a. Trulicity utilization

- i. Due to recent trends of GLP-1 RA being used for off-label for weight loss, HFS looked at the utilization of Trulicity.
- ii. One of the IL Medicaid MCOs suggested a diagnosis edit due to increased off-label utilization of Trulicity for weight loss.
- iii. Current Trulicity FDA indications:
 1. Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with T2DM.
 2. Reduce the risk of major adverse cardiovascular events in adults with T2DM who have established cardiovascular disease or multiple cardiovascular risk factors.



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

- iv. Current HFS policy:
 - 1. Administrative Code: Section 140.441 Pharmacy services not covered- items excluded from coverage include the following: anorectic drugs or combinations including such drugs.
 - 2. State Plan Amendment (SPA) excluded drug classes: agents when used for anorexia, weight loss, weight gain
- v. Recommendations
 - 1. No action
 - 2. Process the claim for Trulicity against a medical record file diagnosis.
 - 3. Add the ability for the pharmacy to document the patient's diagnosis of T2DM on the claim to point #2.
- vi. Discussion
 - 1. Aetna provided comments on their data showing a continued increase of around 12% in claim volume for Trulicity every month. They asked if pharmacists at the point-of-service (POS) can provide a diagnosis code similar to anti-epileptic drugs.
 - 2. The board choose to not make any changes to the current HFS policy at this time. They would like to come back to this topic in the future.

VI. Public Comments

- a. None

VII. Updates – Presented by Sheri Dolan, BSP Pharm

- a. Albuterol syrup
 - i. On 4/6/2023 the D&T Advisory Board discussed the utilization and guideline recommendations for albuterol syrup.
 - ii. The Board voted to make albuterol syrup non-preferred.
 - iii. This recommendation is in the process of being approved by the Director. Once approved, albuterol syrup will be made non-preferred and reserved for those situations in which an inhalant formulation is not appropriate.
 - iv. Prescriber outreach will be conducted.

VIII. Announcements – Presented by Christina Petrykiw, PharmD, CDCES and Donna Clay, BSP Pharm

- a. American Drug Utilization Review Society (ADURS) Annual Meeting 2023
 - i. Donna Clay mentioned that at the meeting the DOJ had a presentation that suggested tracking certain combinations of drugs: overuse of stimulants for ADHD, combination of stimulants and opioids or stimulants and gabapentin.

IX. Future Agenda Items

- a. July: TBD
- b. October: Hemophilia
- c. Board member suggestions
 - i. Dr. Sreedhar suggested the topic of obesity at a future meeting.

X. Adjournment

- a. Dr. Schriever moved to adjourn the meeting at 10:04am.
 - i. Motion to adjourn made by Dr. An, seconded by Dr. Sreedhar
- b. Vote: In favor- 4 / Against- 0 / Abstentions- 0. Meeting adjourned
- c. Next DUR Board Meeting- Thursday, July 27, 2023



HFS

Illinois Department of
Healthcare and Family Services

JB Pritzker, Governor

201 South Grand Avenue East, Springfield, Illinois 62763

Theresa A. Eagleson, Director

Telephone: +1 217-782-1200, TTY: +1 800-526-5812

Meeting Attendance

DUR Board Members

Christopher Schriever, PharmD, MS, AAHVP, Chair
Radhika Sreedhar, MD, MS, FACP, Vice-Chair
Aneet Ahluwalia, MD
Sam An, PharmD
Bedrija Nikocecic, PharmD, BCACP
Erica Stevens, PharmD, BCGP

Staff/Panelists

Donna Clay, BSP Pharm, Prior Authorization Services – UIC
Claudia Colombo, PharmD – UIC Springfield
Jen DeWitt, BSP Pharm – UIC Springfield
Sheri Dolan, BSP Pharm – UIC Springfield
Arvind Goyal, MD, MPH, MBA - Medical Director, HFS
Jose Jimenez, Bureau Chief – BPAS
Debra Long – BPAS
Mary Moody, BSP Pharm – UIC
Christina Petrykiw, PharmD, CDCES – UIC
Maurice Shaw, PharmD – UIC Springfield
Lori Uildriks, PharmD, BCPS – UIC

Guests/Attendees

Mark Baldrige	JJ Roth
Chad Blomgren	Robin Selsor
Kimbra Brooks	Michele Shirley
John Bullard	Steve Sproat
Lakshmi Emory	Chase Williams
Mark Friederich	Call-In User 2 (217558****)
Kelly Hamilton	
Sakib Hassan	
Clemice Hurst	
Doug Johnson	
Mary Kaneaster	
Jeff Knappen	
Phil Lohec	
Ingrid Ma	
Neelesh Nadkarni	
Daphne Ni	
Keith O'Hara	
Nichole Palusinski	
Cindy Pennington	
Kelly Petrowski	
Pawel Piechocinski	
Kenneth Ring	
Tess Rondestvedt	

Approved July 27, 2023 by the Illinois Drug Utilization Review Board